Alliance Pharma PLC (LON:APH) on Friday told investors that the UK healthcare regulator has not approved a marketing authorisation submission for Diclectin.
The product is a treatment for nausea and vomiting during pregnancy. It was in-licenced from Duchesnay Inc for the UK in 2015 and for a further nine European territories in 2016, and £1.5mln was paid to Duchesnay for all territories.
“Whilst this is disappointing news, this will have no material impact on the company's expected near-term results,” the company said in a note.
The company’s comments were echoed by finnCap analyst Mark Brewer who, in a note, said: “The announcement late on Friday that the UK’s regulator (MHRA) has not approved Diclectin for the treatment of nausea and vomiting of pregnancy (NVP) is clearly a disappointment, although not detrimental to near-term forecasts given the stronger than expected interim trading update.”